Affini-T Therapeutics Doses First Patient in KRAS G12V Phase 1, Presents Poster at ASCO 2024

Affini-T Therapeutics, a biopharmaceutical company specializing in precision immunotherapies for solid tumors, has announced the successful dosing of the first patient in its Phase 1 clinical trial of AFNT-211. This investigational therapy focuses on patients with a KRAS G12V genetic mutation, targeting individuals with limited treatment alternatives. The company will present a Trial-In-Progress poster related to this clinical trial at the upcoming American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago, scheduled from May 31 to June 4.

"We are thrilled to have dosed the first patient in our flagship clinical program," stated Jak Knowles, M.D., Co-Founder, President, and CEO of Affini-T Therapeutics. "This achievement is a testament to the dedication of our scientific co-founders and our commitment to patients. With our initial programs targeting KRAS G12V and ongoing research into KRAS G12D and TP53, we are poised to develop groundbreaking therapies for cancer patients lacking effective treatment options."

Dirk Nagorsen, M.D., the company's Chief Medical Officer, highlighted the significance of AFNT-211. "Our aim is to address the substantial unmet needs of patients with challenging-to-treat solid tumors. AFNT-211 leverages precision immunotherapy and synthetic biology to target the KRAS G12V oncogenic mutation in HLA-A*11:01-positive patients. Since beginning enrollment and treatment in our two programs, AFNT-111 and AFNT-211, earlier this year, we've made remarkable strides in our clinical trial efforts."

The poster presentation at the ASCO meeting will include details such as:
- Title: AFNT-211: A phase 1 study of autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific, transgenic TCR, a CD8α/β coreceptor, and a FAS41BB switch receptor in patients with advanced/metastatic solid tumors.
- Location: Hall A, Abstract # TPS8650, Poster Board # 513a
- Session Title: Lung Cancer—Non-Small Cell Metastatic
- Date/Time: Monday, June 3, 2024, 1:30 PM – 4:30 PM CDT
- Presenting Author: Shaunica Mitchell, M.P.A., Senior Director, Clinical Science, Clinical Development at Affini-T Therapeutics

AFNT-211 is an autologous T cell therapy designed for adult patients with solid tumors harboring the KRAS G12V mutation. This Phase 1 clinical trial aims to evaluate the therapy's safety and efficacy. More information about the trial can be found at clinicaltrials.gov under the identifier NCT06105021.

Affini-T Therapeutics is at the forefront of precision immunotherapy, targeting key oncogenic mutations like KRAS and TP53. The company is developing two primary therapeutic approaches: adoptive cellular therapies and bispecific T cell engagers. These modalities aim to harness T cell immunity with high specificity and potency against solid tumors. The company's TCR-T cell therapy platforms incorporate advanced engineering, synthetic biology, and gene editing to optimize T cell functions and modify the tumor microenvironment. Additionally, the bispecific T cell engager platform employs high-throughput affinity maturation and biologics format constructions to target oncogenic mutations with precision.

Affini-T's commitment to innovation is driven by its leadership team's expertise and technological capabilities, empowering the company to develop transformative treatments with lasting impact.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!